Business
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older
-- Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 -- -- Vaxcyte Remains on Track to Announce
About this update from Vaxcyte, Inc.
[{"type":"text","content":"-- Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 -- -- Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study in Adults Aged 18-64 in October or November 2022 -- -- VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection to Prevent Invasive Pneumococcal Disease -- SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in the Phase 2 study evaluating VAX-24 in healthy adults 65 years of age and older. VAX-24 is the Company’s lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD). This Phase 2 clinical study, which is now fully enrolled with approximately 200 participants, is a randomized, observer-blind, dose-finding study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in adults 65 years of age and older. Vaxcyte expects to announce topline safety, tolerability and immunogenicity results from this Phase 2 study in the first half of 2023. “Completing the enrollment of the VAX-24 study in adults 65 years and older is a significant step toward understanding the full clinical potential of our lead vaccine candidate in adults,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “We are very pleased with the progress made to advance the VAX-24 clinical program and we remain on track to announce the topline data from the VAX-24 Phase 1/2 study in adults 18-64 years of age in October or November of this year, as well as the topline data from the study in adults 65 and older in the first half of 2023.” “VAX-24 was granted Fast Track designation in adults by the FDA, which we believe provides an expedited path to deliver VAX-24 to adults and underscores the need for a PCV that provides broader protection to prevent this serious disease,” said Jim Wassil, Executive Vice President and Chief Operating Officer of Vaxcyte. “Older adults are at increased risk for pneumococcal disease and severe complications, making the need for a broad-spectrum P...